View in EDS PDF Full Text

Off-label use of rituximab in systemic rheumatic diseases: case series.

Saved in:
Bibliographic Details
Title: Off-label use of rituximab in systemic rheumatic diseases: case series.
Authors: Araújo, Filipe1,2 flipar@msn.com, Silva, Inês1, Sepriano, Alexandre1,3, Nero, Patrícia1,4, Branco, Jaime C.1,4
Source: Acta Reumatológica Portuguesa. out-dez2013, Vol. 38 Issue 4, p290-294. 5p.
Subjects: RITUXIMAB, RHEUMATISM treatment, B cells, HUMORAL immunity, BLOOD plasma, ANTIBODY formation, PHYSIOLOGY
Abstract: B-cells play an important role not only in cellular but also in humoral immunity through differentiation into plasma cells and antibody production. B-cell depletion may, theoretically, change the course of systemic rheumatic diseases (SRD) in which self-reactive antibodies are part of the pathogenic pathway. In Rheumatology, anti-B-cell antibody Rituximab is currently licensed for the treatment of rheumatoid arthritis, however there is growing evidence of its potential use in other SRD. The authors present a case series of eight patients in which Rituximab was used off-label including overlap syndrome Rhupus, systemic lupus erythematosus and Wegener's granulomatosis. In the end, a brief literature review about this subject is performed. [ABSTRACT FROM AUTHOR]
Copyright of Acta Reumatológica Portuguesa is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:B-cells play an important role not only in cellular but also in humoral immunity through differentiation into plasma cells and antibody production. B-cell depletion may, theoretically, change the course of systemic rheumatic diseases (SRD) in which self-reactive antibodies are part of the pathogenic pathway. In Rheumatology, anti-B-cell antibody Rituximab is currently licensed for the treatment of rheumatoid arthritis, however there is growing evidence of its potential use in other SRD. The authors present a case series of eight patients in which Rituximab was used off-label including overlap syndrome Rhupus, systemic lupus erythematosus and Wegener's granulomatosis. In the end, a brief literature review about this subject is performed. [ABSTRACT FROM AUTHOR]
ISSN:0303464X